Skip to main content

News

2025 ACR Guidance on Diagnosis and Management of VEXAS

The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management. 

IBS in America

Despite advances, IBS remains a burden for many millions.

Repurposing & Pipeline (8.8.2025)

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.

Dermatomyositis Reviewed

Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.

Inefficiencies of ANA Testing

The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs).

Smoking and the Global Burden of Rheumatoid Arthritis

Detailed analysis of the Global Burden of Disease (GBD) 2021 database shows that tobacco and smoking is one of the most significant environmental risk factors for Rheumatoid Arthritis (RA) over the last 20 years. 

RA leads to ILD: but ILD does not lead to RA

Rheumatoid arthritis is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

Juvenile Idiopathic Arthritis - NEJM Review

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).

2025 BSR Recommendations for ANCA-associated Vasculitis

The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA).

Rheums Speak - RA Treatment Survey

RheumNow's August 2025 “Live Vote” surveys examine Rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. The first survey on RA Treatment (7/28/2025) sheds light on evolving prescribing habits, use of biologics, and key frustrations in RA care.

Aging Quiets Lupus

EurekAlert!
UCSF researchers have found that epigentic changes in interferon genes over time may lead to lupus being less active as they age. Lupus is a “classic” autoimmune disease. It causes the immune system’s first-line viral defenses — known as interferons — to attack the body. Nearly every organ is at risk, leading to conditions like kidney and heart disease. But unlike many other autoimmune or chronic illnesses, lupus can improve as patients reach their 60s and 70s.

A New RA Approval (8.1.2025)

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

×